uploads/2018/02/Enbrel.png

Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017

By

Updated

PFE’s inflammation and immunology portfolio revenue trends

In 4Q17, Pfizer’s (PFE) inflammation and immunology portfolio reported revenues of $1.1 billion, which reflected a ~8% rise on a YoY (year-over-year) basis. In 4Q17, in the US and outside the US, Pfizer’s inflammation and immunology portfolios generated revenues of $390 million and $714 million, respectively, compared with $259 million and $763 million in 4Q16.

In fiscal 2017, Pfizer’s inflammation and immunology portfolio generated revenues of $3.97 billion, which was ~1% higher on a YoY basis. In 2017, in the US and in international markets, Pfizer’s the portfolio generated revenues of $1.27 billion and $2.70 billion, respectively, compared with $845 million and $3.08 billion in 2016.

Article continues below advertisement

Enbrel revenue trends

In 4Q17, Pfizer’s (PFE) Enbrel generated revenues of $634 million, which represents a ~10% decline on a YoY basis. Pfizer commercializes Enbrel in markets outside the US and Canada. Amgen commercializes Enbrel in the US and in Canada. In 4Q17, Amgen reported revenues of $1.42 billion from the sales of Enbrel.

In fiscal 2017, Enbrel reported revenues of $2.45 billion, which represents a ~16% YoY decline. In 2017, in the US and in international markets, Enbrel reported revenues of $1.1 billion and $212 million, respectively, compared with $805 million and $122 million in 2016.

In the rheumatoid arthritis drug market, Pfizer’s Enbrel competes with AbbVie’s (ABBV) Humira, Johnson & Johnson’s (JNJ) Remicade, and Roche’s (RHHBY) Rituxan.

Eucrisa revenue trends

In 4Q17, Eucrisa reported revenues of $34 million. In 2017, Eucrisa reported revenues of $67 million.

Eucrisa (crisaborole) is used for the treatment of individuals older than two with mild to moderate atopic dermatitis. Some notable drugs for atopic dermatitis in the marketplace include Valeant Pharmaceuticals’ Elidel and Leo Pharma’s Protopic.

In the next part of this series, we’ll discuss the performance of Pfizer’s Xeljanz in detail.

Advertisement

More From Market Realist